GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15 at 9:00 a.m. PT in San Francisco. Interested parties can access both live and replay webcasts through the investor relations section of GRAIL's website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GRAL declined 5.25%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302335384.html
SOURCE GRAIL, Inc.